ARTICLE | Clinical News

Enzychem starts Phase II of mosedipimod for chemotherapy-induced neutropenia

July 28, 2017 6:11 AM UTC

Enzychem Lifesciences Corp. (KONEX:183490) began a Phase II trial of mosedipimod (EC-18) to treat chemotherapy-induced neutropenia (CIN) in patients with breast cancer. The 2-part, Korean trial will evaluate 500, 1,000, 1,500 and 2,000 mg doses of oral mosedipimod in patients receiving second-line or higher chemotherapy whose risk level for febrile neutropenia is low.

The open-label, dose-escalation part 1 will enroll 12 patients to determine the maximum tolerated dose (MTD). The double-blind, placebo-controlled part 2 will enroll 65 patients to receive the MTD. The trial’s primary endpoint is the duration of grade 4 neutropenia and the secondary endpoint is safety...